GlassScriptPhysician profile
Monica V Ramirez
NPI 1417114356
$6,383.90
in general payments reported to CMS, 2019-2025
23 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,746 · 2020: $160 · 2021: $894 · 2022: $1,134 · 2023: $686 · 2024: $742 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,449.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,657.60 | 2019-2025 | Clareon, Eysuvis, Tryptyr |
| Glaukos Corporation | $656.65 | 2021-2025 | Radius, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Novartis Pharmaceuticals Corporation | $533.65 | 2019-2022 | |
| Biotissue Holdings INC. | $530.81 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $529.49 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Allergan, INC. | $277.49 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $235.03 | 2019-2021 | |
| Dompe US, INC. | $219.07 | 2019-2025 | Oxervate |
| Genmab U.S., INC. | $200.62 | 2022-2023 | Tivdak |
| Tarsus Pharmaceuticals, INC. | $196.58 | 2024-2025 | Xdemvy |
| Synergeyes, INC. | $191.74 | 2022 | |
| Kala Pharmaceuticals, INC. | $184.60 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $172.52 | 2019-2025 | |
| Abbvie INC. | $162.92 | 2022-2025 | |
| Oyster Point Pharma, INC. | $124.50 | 2022-2025 | Tyrvaya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $124.34 | 2022 | |
| Eyevance Pharmaceuticals LLC | $113.40 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $96.38 | 2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.23 | 2019-2020 | |
| Astellas Pharma US INC | $36.05 | 2024-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $24.18 | 2020 | |
| Mallinckrodt Enterprises LLC | $21.11 | 2019 | |
| Sight Sciences, INC. | $15.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.